Oragenics Co-Authors a Publication Describing the Dual Mechanism of Action of Lantibiotics
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc., in collaboration with researchers from Florida International University’s Department of Physics and Biomolecular Sciences Institute, announced the publication of a study entitled “Lipid II Binding and Transmembrane Properties of Various Antimicrobial Lanthipeptides.”
Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate
UF startup and Sid Martin Biotech alumni company Oragenics, Inc. announced the results from its study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study. The study provided preclinical data for formulations designed for both intranasal and intramuscular administration.
Oragenics Awarded a $250,000 Grant From the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc., announced that it was awarded a small business innovation research grant in the amount of $250,000 (Computer-aided Design for Improved Lantibiotics R41GM136034) for the company’s continued research and development of lantibiotics, including its collaborative program with the Biomolecular Sciences Institute at Florida International University (FIU).
Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of Its SARS-CoV-2 Vaccine Candidate
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc. announced the initiation of a study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study.
Oragenics’ SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice With Intramuscular and Intranasal Adjuvants
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announces that the stabilized pre-fusion spike protein trimer produced by its Canadian collaborator and licensed by the company from the National Institutes of Health (NIH) generates neutralizing antibodies in mice after immunization against SARS-CoV-2, when administered with several novel intramuscular (IM) and intranasal (IN) adjuvants.
Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced it has entered into a licensing agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.
Tampa Bay Company Searching for Other Vaccine Methods
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, is in the pre-clinical phase of developing a vaccine they say would solve two critical problems when it comes to ending the pandemic.
Oragenics Chases Vaccine for Niche Markets
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, seeks to be a major player in the Super Bowl of the pharmaceutical industry: a COVID-19 vaccine.
Biotech Firm Raises $20 Million, Sees Progress on COVID-19 Vaccine
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc. has raised $20 million from the sale of common stock and will use some of the funding to boost its research into a Covid-19 vaccine.
SARS-CoV-2 Spike Protein Licensed by Oragenics From the NIH Demonstrates Protective Immunity in Mice
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announces that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National Institutes of Health (“NIH”) and licensed by the Company demonstrates protective immunity in immunized mice challenged with mouse-adapted SARS-CoV-2 virus.
